The invention relates to a bendmustine 
hydrochloride compound and a method for preparing the same. The bendmustine 
hydrochloride compound prepared by the method can be used for treating 
chronic lymphocytic leukemia (CLL) and 
inertia B-
cell non-Hodgkin's 
lymphoma (B-
cell NHL). The bendmustine 
hydrochloride compound contains bendmustine hydrochloride and hydroxyproyl beta-
cyclodextrin, wherein the 
mass ratio of bendmustine hydrochloride to hydroxyproyl beta-
cyclodextrin is 1:1-20. During the preparation process, mixed 
solvent of 
tertiary butanol and water for injection can be used, wherein the concentration of bendmustine hydrochloride in the mixed 
solvent is 5-10mg / mL; the ratio in the 
solvent (100%) by volume is as follows: 5-50% of 
tertiary butanol and the balance of water. The preparation process comprises the following steps of: weighing the 
tertiary butanol, sequentially adding the solvent and the hydroxyproyl beta-
cyclodextrin, dissolving, evenly mixing and cooling the mixture to 2-15 DEG C, maintaining the temperature, then adding the bendmustine hydrochloride, stirring until bendmustine hydrochloride dissolves, filtering, filling, stoppering, dishing-up, freeze-
drying, corking, out-box, covering and packaging, and finally, the bendmustine hydrochloride compound is obtained.